Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (675)	1/21/2005 4:08:04 PM
From: Jibacoa	Respond to of 3722

AVXT Is up more than 16% on moderate volume of 79,622. It needs to close above its Dec.28-Dec.29 double top at the $0.37 level.(If it can do that it could get to test its April H at $0.40 or even its Feb. H at $0.51 <g>) Back in December,it announced that it received an OK from the FDA that it may begin a clinical trial of its autologous, hapten-modified melanoma vaccine, M-Vax bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (675)	8/24/2005 1:52:18 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

CURN has been forming a base at the $0.40 level for the past month. On August 5 the volume increased to 1,563,068 on an upmove from $0.34 to $0.46 <g> bigcharts.marketwatch.com On July 21, it announced its 2ndQ results, which showed a 24% increase in revenues and said that the record sales of its Secca products for bowel incontinence and increased sales of its Stretta products for GERD were able to generate "positive gross margins" for first time.<g> Back in April it raised around $12M with private investors on a sale of common stock and warrants for 5 years with an exercise price of $1. As previously mentioned, the insiders reportedly have been buying and the D/E is around 0.07 <g> If the stock can get to retest the $2.02 level it had on January 6 it would be a good % gain.<g> bigcharts.marketwatch.com Bernard